Morgan Stanley Maintains Overweight on Generate Biomedicines, Raises Price Target to $22
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. GENB | 0.00 |
Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:
GENB) with a Overweight and raises the price target from $20 to $22.